GNQ Insilico Plans to Accelerate Precision Medicine and Clinical AI Adoption Across Drug Development and Patient Care
The new service offering combines GNQ Insilico’s Causal AI Drug Assessment, Drug Simulation, and Digital Twin platforms with IBM’s consulting and hybrid cloud expertise. SAN JOSE, Calif.–(BUSINESS WIRE)–GNQ Insilico, Inc. (GNQ), a precision medicine TechBio company, today announced a collaboration with IBM aimed to help healthcare and life sciences organizations accelerate the adoption of personalized, […]